Citation Impact
Citing Papers
Matrix Protein CCN1 Is Critical for Prostate Carcinoma Cell Proliferation and TRAIL-Induced Apoptosis
2009 Standout
Antitumor polyketide biosynthesis by an uncultivated bacterial symbiont of the marine sponge Theonella swinhoei
2004 Standout
Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidin™
2004
Adding pharmacogenomics to the development of new marine-derived anticancer agents
2006
Genome-wide characterization of simple sequence repeats in cucumber (Cucumis sativus L.)
2010 Standout
Chemosensitivity linked to p73 function
2003 StandoutNobel
Pyrophosphate-bridged complexes with picomolar toxicity
2009
Dexfenfluramine, Fluoxetine, and Weight Loss Among Female Carbohydrate Cravers
1993
Molecular, pharmacological and functional diversity of 5-HT receptors
2002 Standout
Marine-derived anticancer agents in clinical trials
2003
VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia
2005
Natural products: An evolving role in future drug discovery
2011 Standout
Ovarian cancer
2014 Standout
Clinical development and potential of photothermal and photodynamic therapies for cancer
2020 Standout
Marine natural products
1990 Standout
Drug development from marine natural products
2008 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Gene expression profile changes in initiation and progression of squamous cell carcinoma of esophagus
2001
Microsatellite analysis at 1p36.3 in malignant melanoma of the skin
2003
Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors
1995 StandoutNatureNobel
Molecular mechanisms of resistance and toxicity associated with platinating agents
2006 Standout
Endocrine Factors in Common Epithelial Ovarian Cancer*
1991
JNK activation is critical for Aplidin™-induced apoptosis
2004
Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors
2001
Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program.
1993
Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4
2003
New Drugs from the Sea
2004
Death receptors: Targets for cancer therapy
2009
Marine pharmacology in 2001–2: antitumour and cytotoxic compounds
2004
Amygdaloid central nucleus lesions and cholinergic blockade attenuate the response of the renal peripheral benzodiazepine receptor to stress
1993
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Progress in the development and acquisition of anticancer agents from marine sources
2003
Phenylethanolaminotetralines compete with [3H]dihydroalprenolol binding to rat colon membranes without evidencing atypical β-adrenergic sites
1992
Cellular processing of platinum anticancer drugs
2005 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer
2003
A within-trial cost-effectiveness analysis of primary care referral to a commercial provider for weight loss treatment, relative to standard care—an international randomised controlled trial
2012 Standout
Hormone receptors in malignancy
1992
Microsatellites: genomic distribution, putative functions and mutational mechanisms: a review
2002
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
In vitro cytotoxicity of aplidin and crossresistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples: a rational basis for clinical development
2003
Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma
2003
Live or let die: the cell's response to p53
2002 Standout
Using next‐generation sequencing approaches to isolate simple sequence repeat (SSR) loci in the plant sciences
2011 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Polyaromatic alkaloids from marine invertebrates as cytotoxic compounds and inhibitors of multidrug resistance caused by P-glycoprotein
1996
Activation of apoptosis signalling pathways by reactive oxygen species
2016 Standout
Transactivation of miR-34a by p53 Broadly Influences Gene Expression and Promotes Apoptosis
2007 Standout
Neurosteroid biosynthesis: Enzymatic pathways and neuroendocrine regulation by neurotransmitters and neuropeptides
2009
Mechanisms of Resistance to Photodynamic Therapy
2011
Recognition of cisplatin adducts by cellular proteins
2001
Antiangiogenic activity of aplidine, a new agent of marine origin
2004
Effect of Aplidin in acute lymphoblastic leukaemia cells
2003
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
2008
Marine natural products as inhibitors of hypoxic signaling in tumors
2009
Estrogen replacement therapy for ovarian carcinoma survivors
1999
Targeting the Folate Receptor (FR): Imaging and Cytotoxicity of ReI Conjugates in FR‐Overexpressing Cancer Cells
2008
Didemnins, tamandarins and related natural products
2012
To kill a tumor cell: the potential of proapoptotic receptor agonists
2008
Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines
2004
Cancer Statistics, 2002
2002 Standout
Progress in the clinical development of new marine-derived anticancer compounds
2004
p73: Friend or foe in tumorigenesis
2002
Serotonin and the biology of feeding
1992
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Accumulation of the FACT complex, as well as histone H3.3, serves as a target marker for somatic hypermutation
2013 StandoutNobel
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
2009 StandoutScience
Adipose tissue dynamics and regulation, revisited
2007
EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals
2015 Standout
Levels of p27kip1 determine Aplidin sensitivity
2007
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
1994 Standout
Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia
1997 Standout
Photodynamic Tumor Therapy: Mitochondrial Benzodiazepine Receptors as a Therapeutic Target
1998
Organometallic Anticancer Compounds
2010 Standout
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
1999 Standout
Formation and Release of a Hormone Antagonist by Rat Adipocytes
1971 StandoutNobel
Role of O6-alkylguanine-DNA alkyltransferase in protecting against cyclophosphamide-induced toxicity and mutagenicity.
1999
DNA Mismatch Repair: Functions and Mechanisms
2005 StandoutNobel
New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials
2004
Basic principles of photodynamic therapy
2001 Standout
Ischemic Cell Death in Brain Neurons
1999 Standout
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Aplidine: A Paradigm of how to Handle the Activity and Toxicity of a Novel Marine Anticancer Poison
2007
Advances in Copper Complexes as Anticancer Agents
2013 Standout
Bioactive Peptides and Depsipeptides with Anticancer Potential: Sources from Marine Animals
2012
Telomere-Homologous G-Rich Oligonucleotides Sensitize Human Ovarian Cancer Cells to TRAIL-Induced Growth Inhibition and Apoptosis
2013
Rapid and selective apoptosis in human leukemic cells induced by Aplidine through a Fas/CD95- and mitochondrial-mediated mechanism.
2003
In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells
2003
Drug Resistance in Cancer: An Overview
2014 Standout
Lamellarins and Related Pyrrole-Derived Alkaloids from Marine Organisms
2007 Standout
The Influence of Repair Pathways on the Cytotoxicity and Mutagenicity Induced by the Pyridyloxobutylation Pathway of Tobacco-Specific Nitrosamines
2009 StandoutNobel
Synthesis and biological activity of pyrrole, pyrroline and pyrrolidine derivatives with two aryl groups on adjacent positions
2006 Standout
Phorbol Esters: Structure, Biological Activity, and Toxicity in Animals
2007 Standout
Oestrogen and progesterone receptors in ovarian carcinoma
1998
Works of A.M. Codegoni being referenced
Trail activity in human ovarian cancer cells
2002
Diazepam binding inhibitor (DBI) increases after acute stress in rat
1991
Hepatic protoporphyria is associated with a decrease in ligand binding for the mitochondrial benzodiazepine receptors in the liver
1992
DNA-topoisomerase I activity and content in epithelial ovarian cancer
1998
Expression of Genes of Potential Importance in the Response to Chemotherapy and DNA Repair in Patients with Ovarian Cancer
1997
Progress report on the anorexia induced by drugs believed to mimic some of the effects of serotonin on the central nervous system
1992
Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine
2002
Different vimentin expression in two clones derived from a human colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin
1995
Allelic expression of p73 in human ovarian cancers
1999
Atypical β-adrenoceptors account for inhibition of rat colon motility and lipolytic action of phaenylethanolaminotetraiines
1990
Steroid receptors in epithelial ovarian carcinoma: relation to clinical parameters and survival.
1988
Microsatellite instability and frameshift mutations in genes involved in cell cycle progression or apoptosis in ovarian cancer.
1999
Salicylate, a Powerful Inhibitor of Free Fatty Acid Release
1964 Nature
Molecular characterisation of a panel of human ovarian carcinoma xenografts
1998